Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2022 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Vaccine. 2022 Mar 18;40(13):2044-2052. doi: 10.1016/j.vaccine.2022.02.030. Epub 2022 Feb 8.
Vaccine. 2022.
PMID: 35177302
Free PMC article.
Clinical Trial.
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
Masuda T, Murakami K, Sugiura K, Sakui S, Schuring RP, Mori M.
Masuda T, et al.
Vaccine. 2022 May 26;40(24):3380-3388. doi: 10.1016/j.vaccine.2022.04.035. Epub 2022 Apr 29.
Vaccine. 2022.
PMID: 35501178
Free PMC article.
Clinical Trial.
Item in Clipboard
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Kuriyama K, Murakami K, Masuda T, Sugiura K, Sakui S, Schuring RP, Mori M.
Kuriyama K, et al.
Vaccine. 2023 Jun 7;41(25):3763-3771. doi: 10.1016/j.vaccine.2023.05.001. Epub 2023 May 8.
Vaccine. 2023.
PMID: 37198021
Free PMC article.
Item in Clipboard
[Current status and problem of occupational health and safety of occupational diving workers in Malaysia].
Morimatsu Y, Nishikiori H, Okahara Y, Kojima Y, Kinoshita S, Mori M, Hoshiko M, Ishitake T.
Morimatsu Y, et al.
Sangyo Eiseigaku Zasshi. 2020 Jul 25;62(4):165-167. doi: 10.1539/sangyoeisei.2019-021-W. Epub 2020 Jan 24.
Sangyo Eiseigaku Zasshi. 2020.
PMID: 31983700
Free article.
Japanese.
No abstract available.
Item in Clipboard
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
Kuriyama K, Murakami K, Sugiura K, Sakui S, Schuring RP, Masuda T, Mori M.
Kuriyama K, et al.
Vaccine. 2024 Feb 27;42(6):1319-1325. doi: 10.1016/j.vaccine.2024.01.056. Epub 2024 Feb 2.
Vaccine. 2024.
PMID: 38310018
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite